# Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases

> **NCT07674693** · PHASE1 · NOT_YET_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 29 (estimated)

## Conditions studied

- Leptomeningeal Metastases

## Interventions

- **DRUG:** 186RNL

## Key facts

- **NCT ID:** NCT07674693
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-07
- **Final completion:** 2031-07
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674693, "Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07674693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*